AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

AstraZeneca’s financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadership and pipeline momentum.

Oncology Fuels Revenue Surge

Oncology contributed 44% of product revenue at $25.6 billion (17% CER growth), with key drivers including Tagrisso ($7.3 billion, +10% CER), Imfinzi ($6.1 billion, +28% CER), and Enhertu ($2.8 billion AstraZeneca share, +40% CER). Tagrisso dominated first-line EGFRm NSCLC, Imfinzi expanded across lung, GI, and GU indications with new US approvals, and Enhertu accelerated in earlier-line breast cancer and China. These assets, backed by 14 Phase III trials, target mid-teens growth into 2026 and over $10 billion in combined risk-adjusted peak-year revenue.

BioPharma Holds Steady Amid Challenges

BioPharmaceuticals revenue reached $22.0 billion (5% CER growth), with CVRM at $12.8 billion (+2% CER) led by Farxiga ($8.4 billion, +9% CER) in HF and CKD, and R&I at $8.9 billion (+12% CER) featuring Tezspire (+64% CER to $1.1 billion) and Fasenra (+16% CER). CER methodology isolated operational gains, with US (43%) and China (11%) demand supporting R&D at 24% of revenue for trials like CARDIO-TTRansform.

Rare Disease Expands Reach

Rare Disease generated $9.1 billion (+5% CER), highlighted by Ultomiris ($4.7 billion, +19% CER) in PNH and gMG, and Strensiq ($1.7 billion, +18% CER) in HPP. Launches in over 75 countries and upcoming drivers like ICAN in IgAN position it for low double-digit CAGR.

Profitability and Investments Accelerate

Core operating profit hit $18.5 billion (31% margin, +9% CER), with R&D up 12% CER to $13.8 billion funding 100+ Phase III trials, ADCs, and IO bispecifics. Net debt improved to 1.2x EBITDA, with FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth.

Pipeline Promises $10B+ Opportunities

Over 100 Phase III trials, with 20+ 2026 readouts (>10bn PYR), include camizestrant in ESR1m breast cancer, elecoglipron in obesity/CV, and cliramitug in ATTR-CM. These deepen late-stage assets (37 in Phase III/registration), mitigate LOE risks, and enhance HEOR for market access. The AstraZeneca financial results position the company toward its $80 billion revenue goal by 2030.